<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-157501" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Cystinosis</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Sharma</surname>
            <given-names>Lokesh</given-names>
          </name>
          <aff>Medanta hospital, Lucknow</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Rout</surname>
            <given-names>Preeti</given-names>
          </name>
          <aff>Wilson Case Western University</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Lokesh Sharma declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Preeti Rout declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>8</day>
          <month>9</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-157501.s1" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Cystinosis is a rare autosomal recessive lysosomal storage disorder caused by mutations in the <italic toggle="yes">CTNS</italic> gene, which encodes the cystinosin protein. This disorder&#x000a0;affects an estimated 1 in 100,000 to 200,000 live births worldwide. Cystinosis&#x000a0;is characterized by the accumulation of cystine within cellular lysosomes, ultimately affecting almost all organs.<xref ref-type="bibr" rid="article-157501.r1">[1]</xref>&#x000a0;</p>
        <p>Renal involvement, characterized by proximal tubulopathy, is the most common cause of morbidity and mortality in nephropathic or infantile cystinosis and eventually leads to renal failure. Cystinosis is also the most common inherited cause of Fanconi syndrome in children. The 3 known forms of cystinosis are infantile (nephropathic), juvenile (intermediate and late-onset), and adult (benign, ocular, and non-nephropathic).</p>
        <p>The infantile form is the most common and severe, accounting for about 95% of cases, and typically leads to end-stage renal disease (ESRD) by ages 10 to 12. Cysteamine, a cystine-depleting therapy, is the cornerstone of treatment for this disorder. Early recognition and treatment with cysteamine can delay the progression to ESRD and associated morbidities, resulting in improved overall outcomes.</p>
      </sec>
      <sec id="article-157501.s2" sec-type="Etiology">
        <title>Etiology</title>
        <p>Cystinosis is caused by a malfunctioning protein named cystinosin, which is encoded by the <italic toggle="yes">CTNS</italic> gene on chromosome 17p13.2. Cystinosin is a lysosomal membrane transporter responsible for transporting cystine out of lysosomes. Biallelic mutations in the&#x000a0;<italic toggle="yes">CTNS</italic>&#x000a0;gene result in defective cystinosin production. More than 140 pathogenic mutations have been identified as causing cystinosis.<xref ref-type="bibr" rid="article-157501.r2">[2]</xref>&#x000a0;Larger or truncating mutations are associated with a severe form of cystinosis. Patients with these mutations typically develop infantile (nephropathic) cystinosis. In contrast, those with juvenile or adult forms usually have milder mutations, which allow some cystine transport out of lysosomes.<xref ref-type="bibr" rid="article-157501.r3">[3]</xref></p>
      </sec>
      <sec id="article-157501.s3" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Cystinosis affects approximately 1 in 200,000 live births worldwide, although incidence varies significantly by geographical location.<xref ref-type="bibr" rid="article-157501.r1">[1]</xref>&#x000a0;Due&#x000a0;to its autosomal recessive inheritance pattern, regions with high consanguinity or founder effects show much higher incidences. For instance, the incidence in Brittany, France, is as high as 1 in 26,000 live births, while in Quebec, Canada, it is 1 in 62,500 live births.<xref ref-type="bibr" rid="article-157501.r4">[4]</xref> The highest known incidence of cystinosis is among the Pakistani ethnic group living in the West Midlands, UK, at 1 in 3600 births. Prevalence appears higher in regions where consanguineous marriages are more common, such as the Middle East and North Africa, although specific statistics are unavailable.<xref ref-type="bibr" rid="article-157501.r5">[5]</xref></p>
      </sec>
      <sec id="article-157501.s4" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Cystine is produced through protein catabolism in lysosomes and is a covalently linked dimer of the amino acid cysteine. Under normal conditions, cystinosin transports cystine out of lysosomes, allowing it to be reused by cells. In cystinosis, the defective cystinosin protein cannot transport cystine, causing it to accumulate in lysosomes. This results in cystine crystal buildup in cells across various organ systems. Cystine accumulation leads to cell injury and apoptosis due to increased oxidative stress, impaired chaperone-mediated autophagy, ATP depletion, and damage to other cellular transporters.<xref ref-type="bibr" rid="article-157501.r6">[6]</xref></p>
        <p>Cell damage and apoptosis ultimately result in dysfunction across multiple organ systems. A varying degree of loss of function of the same CTNS gene is responsible for the 3 forms of cystinosis.&#x000a0;Large deletions or variants leading to significant protein truncation are associated with the most severe form, infantile cystinosis. In contrast, inheritance of a milder variant on one or both alleles leads to juvenile (intermediate and late-onset) and benign (adult, ocular, and non-nephropathic) cystinosis.</p>
        <p>Manifestations of underlying&#x000a0;renal impairment are a key feature of cystinosis, with proximal tubulopathy caused by cystine crystal deposition leading to glycosuria, aminoaciduria, phosphaturia, bicarbonaturia, and other electrolyte&#x000a0;losses. Animal studies suggest this is due to the loss of proximal tubular receptors such as megalin and cubilin, SGLT2, and NaPi-IIa transporters.<xref ref-type="bibr" rid="article-157501.r5">[5]</xref>&#x000a0;</p>
        <p>This solute loss and reduced concentrating ability of the proximal tubules result in polyuria, polydipsia, growth failure, and rickets. Over time, proteinuria and renal injury progress to ESRD. Ocular manifestations are caused by cystine crystal deposition in the cornea and conjunctiva, and they present as watery eyes, photophobia, and blepharospasm, with hemorrhagic retinopathy being a rare complication. Nearly all affected children develop corneal cystine crystals by 18 months of age. In addition to the kidneys, the eyes and endocrine organs are commonly affected, typically manifesting later than the renal signs and symptoms.<xref ref-type="bibr" rid="article-157501.r5">[5]</xref>&#x000a0;</p>
        <p>The commonly affected endocrine organs include the thyroid, endocrine pancreas, and gonads.<xref ref-type="bibr" rid="article-157501.r7">[7]</xref>&#x000a0;Primary&#x000a0;hypothyroidism and gonadal failure are more frequent than hypothalamic-pituitary involvement. Later in life, neuromuscular involvement&#x02014;often characterized by difficulty swallowing and walking, metabolic bone disease, and premature vascular calcifications&#x02014;can increase the morbidity of affected individuals. In addition, the accumulation of cystine crystals can cause coarsening of the facial features.<xref ref-type="bibr" rid="article-157501.r8">[8]</xref></p>
      </sec>
      <sec id="article-157501.s5" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>Renal histopathological changes in infantile nephropathic cystinosis include severe proximal tubular lesions, multinucleated podocytes, and cystine crystal deposition, primarily in interstitial cells and podocytes. Under light microscopy, cystine crystals may appear as empty rectangular structures, although they are not always visible on biopsy. Focal and segmental global sclerosis is common and likely contributes to the significant proteinuria.<xref ref-type="bibr" rid="article-157501.r9">[9]</xref></p>
      </sec>
      <sec id="article-157501.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>
<bold>Infantile Cystinosis</bold>
</p>
        <p>This is by far the most common and severe presentation of cystinosis, accounting for up to 95% of cases. Infants typically present between 6 and 12 months of age with symptoms including failure to thrive, polyuria, polydipsia, electrolyte imbalances, dehydration, vomiting, and constipation.&#x000a0;Phosphaturia, loss of vitamin D binding protein, and decreased activation of 25-vitamin D can lead to vitamin D&#x02013;resistant rickets, as well as osteomalacia and osteoporosis by the second decade of life. Proteinuria is an early sign and may reach nephrotic levels.<xref ref-type="bibr" rid="article-157501.r5">[5]</xref><xref ref-type="bibr" rid="article-157501.r10">[10]</xref>&#x000a0;</p>
        <p>One study showed that growth failure was the most common presentation of infantile cystinosis, occurring in 93% of cases.<xref ref-type="bibr" rid="article-157501.r11">[11]</xref>&#x000a0;By ages 3 to 4 in children, photophobia often develops due to progressive corneal crystal deposition. Serum creatinine levels typically remain normal until age 5, but without treatment, progression to ESRD can occur by ages 10 to 12. Additionally, children may develop hepatomegaly due to cystine deposition in Kupffer cells, which can lead to portal hypertension and splenomegaly. Hypothyroidism, hypogonadism, and diabetes are also common and typically present by the second decade of life.&#x000a0;Neuromuscular dysfunction, such as difficulty walking and swallowing and legal blindness, may occur by the third decade of life.<xref ref-type="bibr" rid="article-157501.r7">[7]</xref></p>
        <p>
<bold>Juvenile or Late-Onset Nephropathic Cystinosis</bold>
</p>
        <p>This form comprises about 5% of cases. Initial symptoms often include ocular discomfort or photophobia. The presentation can vary widely, from mild proteinuria to overt nephrotic syndrome, with growth retardation typically not being a characteristic feature of this form.<xref ref-type="bibr" rid="article-157501.r5">[5]</xref><xref ref-type="bibr" rid="article-157501.r9">[9]</xref> Symptoms usually begin between ages 5 and 20, with less severe progression to ESRD by ages 15 to 30 years or later. Fanconi syndrome is less common in this late-onset form, even when renal involvement is present.<xref ref-type="bibr" rid="article-157501.r9">[9]</xref>&#x000a0;</p>
        <p>
<bold>Adult (Ophthalmic) Cystinosis</bold>
</p>
        <p>This form manifests as visual symptoms, primarily photophobia, from young adulthood to middle age. An eye examination will reveal corneal cystine accumulation, while other systemic symptoms are usually absent.<xref ref-type="bibr" rid="article-157501.r12">[12]</xref></p>
        <p>
<bold>Ophthalmological Examination</bold>
</p>
        <p>Eye abnormalities often represent one of the earliest extra-renal manifestations of cystinosis, making ophthalmological examination crucial for diagnosis. Corneal cystine accumulation with crystal formation is typically the first extra-renal finding and usually becomes apparent by 12 to 18 months of age, requiring a slit-lamp exam for visualization. This crystal formation can lead to photophobia and blepharospasm, generally occurring between mid-childhood and early adolescence.&#x000a0;</p>
        <p>Superficial punctate and filamentary keratopathy are frequently observed in adolescent and adult patients. Band keratopathy, peripheral corneal neovascularization, and posterior synechiae with iridic thickening are often found in older individuals. Depigmentation of the peripheral retina with pigment epithelial mottling is a common posterior segment complication. Approximately 10% to 15% of patients may develop retinal blindness.<xref ref-type="bibr" rid="article-157501.r13">[13]</xref><xref ref-type="bibr" rid="article-157501.r14">[14]</xref><xref ref-type="bibr" rid="article-157501.r15">[15]</xref></p>
        <p>
<bold>Neurological Examination</bold>
</p>
        <p>Neurological findings are common and may include tremors, hypotonia, gross and fine motor impairment, speech delays, neurocognitive dysfunction, behavioral issues, idiopathic intracranial hypertension, and encephalopathy. Progressive distal muscle wasting and weakness are also frequently observed.<xref ref-type="bibr" rid="article-157501.r5">[5]</xref></p>
        <p>
<bold>Other&#x000a0;Physical Examination Findings</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Coarse facial features&#x000a0;<xref ref-type="bibr" rid="article-157501.r8">[8]</xref></p>
          </list-item>
          <list-item>
            <p>Congenital hypopigmentation, including light skin and blond hair, due to impaired melanin production&#x000a0;<xref ref-type="bibr" rid="article-157501.r16">[16]</xref></p>
          </list-item>
          <list-item>
            <p>Growth retardation</p>
          </list-item>
          <list-item>
            <p>Hepatomegaly</p>
          </list-item>
          <list-item>
            <p>Hypogonadism</p>
          </list-item>
          <list-item>
            <p>Premature skin aging&#x000a0;<xref ref-type="bibr" rid="article-157501.r5">[5]</xref>&#x000a0;</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-157501.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Polyuria is often the first notable sign of cystinosis, defined as urine output of more than 2 L/m<sup>2</sup>/d. Once polyuria is confirmed, it is crucial to assess urinary electrolytes, bicarbonate, glucose, and protein levels. All patients with Fanconi syndrome&#x000a0;at a young age should be evaluated for cystinosis unless another cause is known, as cystinosis is the most common hereditary cause of Fanconi syndrome in children.</p>
        <p>
<bold>Common&#x000a0;Diagnostic Findings in&#x000a0;Cystinosis</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Serum electrolytes: Hypokalemia, hypophosphatemia, hypocalcemia, hyponatremia, and low bicarbonate levels&#x000a0;<xref ref-type="bibr" rid="article-157501.r10">[10]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Urinalysis: Low osmolality, glycosuria, tubular proteinuria, phosphaturia, and bicarbonaturia</p>
          </list-item>
          <list-item>
            <p>Arterial blood gas: Non-anion gap metabolic acidosis</p>
          </list-item>
          <list-item>
            <p>Thyroid function: Evidence of hypothyroidism</p>
          </list-item>
          <list-item>
            <p>Hemoglobin A1c (HbA1c): Elevated, indicating persistent hyperglycemia</p>
          </list-item>
          <list-item>
            <p>Sex hormones: Low testosterone levels</p>
          </list-item>
          <list-item>
            <p>Liver function tests: Elevated alanine aminotransferase and aspartate aminotransferase</p>
          </list-item>
          <list-item>
            <p>Vitamin D (1,25-OH): Low with normal vitamin D (25-OH)</p>
          </list-item>
          <list-item>
            <p>Wrist radiography and dual-energy x-ray absorptiometry (DXA): Low bone mineral density, leading to rickets and osteoporosis&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Renal ultrasonography: Nephrocalcinosis</p>
          </list-item>
        </list>
        <p>Leukocyte cystine levels and molecular genetic testing for pathogenic <italic toggle="yes">CTNS</italic> variants are recommended to support a diagnosis of cystinosis. A comprehensive ophthalmological examination is also crucial and cannot be understated. Evaluation of leukocyte cystine levels requires a specialized laboratory. Results are expressed as half-cystine (with 1 molecule of cysteine being half of cystine) per milligram of protein. Generally, levels greater than 2 nmol half-cystine/mg of protein suggest cystinosis. Specifically, levels in the range of 5 to 15 nmol half-cystine/mg of protein indicate infantile cystinosis, while 3 to 6 nmol half-cystine/mg of protein suggest juvenile cystinosis. Patients without cystinosis typically have levels below 0.2 nmol half-cystine/mg of protein.<xref ref-type="bibr" rid="article-157501.r17">[17]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-157501.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>
<bold>Systemic Cysteamine Therapy</bold>
</p>
        <p>Cysteamine is the primary treatment to lower cystine levels. This alkyl amine contains a thiol group that interacts with cystine in lysosomes, forming cysteine (half-cystine) and cysteine-cysteamine complexes. These complexes can be transported out of lysosomes via cysteine and lysine transporters, such as the PQLC2 transporter. Cysteamine therapy significantly delays disease progression and reduces morbidity and mortality across all forms of cystinosis.<xref ref-type="bibr" rid="article-157501.r10">[10]</xref><xref ref-type="bibr" rid="article-157501.r18">[18]</xref></p>
        <p>Early treatment is essential, as it can significantly delay the progression to ESRD, improve growth, and reduce other complications of cystinosis. While cysteamine is generally considered non-curative and primarily delays symptom progression, patients still require aggressive hydration, nutrition, and electrolyte and bicarbonate replacement. However, a recent study demonstrated that early cysteamine treatment in infants can successfully preserve proximal tubular function, with normal electrolyte and bicarbonate levels observed into their second decade of life.<xref ref-type="bibr" rid="article-157501.r19">[19]</xref></p>
        <p>Cysteamine is available in both immediate-release and newer delayed-release formulations. The immediate-release formulation should be initiated at one-sixth of the target dose, given every 6 hours, up to 1.3 g/m&#x000b2;/d for children aged 12 or younger&#x000a0;and 2 g/d for those aged 12 or older or with a body weight of more than 50 kg.<xref ref-type="bibr" rid="article-157501.r17">[17]</xref>&#x000a0;The delayed-release formulation can be administered every 12 hours with equal efficacy.<xref ref-type="bibr" rid="article-157501.r20">[20]</xref>&#x000a0;Transitioning from an immediate- to a delayed-release formulation typically results in a modest dose reduction.</p>
        <p>Leukocyte cystine levels should be monitored regularly, initially monthly and then less frequently as the condition stabilizes, to guide therapy. Cysteamine treatment aims to maintain a mean cystine level of less than 1 nmol/mg of protein in a blood sample taken 6 hours after the last cysteamine dose.<xref ref-type="bibr" rid="article-157501.r17">[17]</xref></p>
        <p>Common adverse reactions to cysteamine include nausea, vomiting, diarrhea, anorexia, abdominal pain, headache, bad breath, sulfuric body odor, hallucinations, nervousness, fever, and skin rash.</p>
        <p>Cysteamine increases gastric acid secretion, making gastrointestinal complications common and potentially leading to medication intolerance. Proton pump inhibitors can help alleviate these symptoms. Due to the metabolism of cysteamine into sulfur products, a bad odor may develop, which can sometimes be managed with riboflavin or chlorophyll supplements.<xref ref-type="bibr" rid="article-157501.r5">[5]</xref> While rare, severe adverse reactions include seizures, neutropenia, and fibrosing colonopathy. Cysteamine therapy should be discontinued during pregnancy due to concerns about potential teratogenic effects.<xref ref-type="bibr" rid="article-157501.r21">[21]</xref>&#x000a0;</p>
        <p>
<bold>Topical Ophthalmic Cysteamine Therapy</bold>
</p>
        <p>Systemic therapy does not address corneal cystine deposition effectively. Topical ophthalmic cysteamine eye drops help prevent and reduce cystine accumulation in the cornea. However, adherence to this therapy is challenging due to the need for application 6 to 10 times daily.<xref ref-type="bibr" rid="article-157501.r22">[22]</xref>&#x000a0;The gel formulation offers a more sustainable option.<xref ref-type="bibr" rid="article-157501.r23">[23]</xref>&#x000a0;</p>
        <p>
<bold>Prostaglandin Inhibitors </bold>
</p>
        <p>Cysteamine therapy does not alleviate symptoms of established Fanconi syndrome. Indomethacin, a prostaglandin inhibitor, has shown variable success in treating conditions such as Bartter syndrome and arginine vasopressin resistance (formerly nephrogenic diabetes insipidus), which involve water and electrolyte loss, resulting in polyuria, polydipsia, and failure to thrive.&#x000a0;In cystinosis, prostaglandin inhibitors, such as indomethacin at doses of 1 to 3 mg/kg/d, have been used with similar aims and yielded variable outcomes.&#x000a0;Precautions are necessary during periods of dehydration, and indomethacin is typically discontinued during these times. Angiotensin-converting enzyme (ACE) inhibitors should be avoided with indomethacin, as their combined use can decrease glomerular filtration rate (GFR) and worsen renal insufficiency.</p>
        <p>
<bold>&#x000a0;Treatment of Complications and Comorbidities</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Adequate fluids, phosphate, potassium, and alkali replacement are essential to compensate for proximal tubular losses. High fluid intake is crucial during fevers, gastroenteritis, and summer months to prevent hypovolemia, which can worsen renal damage.<xref ref-type="bibr" rid="article-157501.r10">[10]</xref><xref ref-type="bibr" rid="article-157501.r24">[24]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Cholecalciferol, calcitriol, phosphate, and alkali supplements help maintain bone health.<xref ref-type="bibr" rid="article-157501.r25">[25]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Growth failure is common in children affected by this condition.<xref ref-type="bibr" rid="article-157501.r11">[11]</xref>&#x000a0;Early initiation of growth hormone therapy is both safe and effective, regardless of growth hormone stimulation results or renal insufficiency.<xref ref-type="bibr" rid="article-157501.r26">[26]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Carnitine therapy has been investigated for muscle wasting but has not shown proven effectiveness. A high-calorie diet remains the primary treatment approach.<xref ref-type="bibr" rid="article-157501.r5">[5]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Thyroid hormone replacement should be administered as needed.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Puberty may begin spontaneously; however, many boys experience gonadal failure in the second decade of life due to cystine deposition in various parts of the testes, which leads to decreased androgen and sperm production. Both nonobstructive and obstructive factors can cause azoospermia. As gonadal failure is primarily due to end-organ failure rather than hypothalamus-pituitary dysfunction, gonadotropin treatment is ineffective for cystinosis-induced hypogonadism. Testosterone replacement should be provided as needed. Fertility preservation, including sperm banking and the option of future assisted reproductive technology, should be offered to all males starting in adolescence. Unlike males, females with cystinosis usually have unaffected gonadal function. However, chronic kidney disease and immunosuppressive therapy for renal transplantation (if needed) can somewhat limit their childbearing potential.&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Splenectomy may be required for splenomegaly or complications of hypersplenism, such as pancytopenia or anemia. According to the Centers for Disease Control and Prevention (CDC), patients undergoing planned splenectomy should receive pneumococcal, meningococcal, and <italic toggle="yes">Haemophilus influenzae</italic> vaccines at least 14 days before surgery.</p>
          </list-item>
        </list>
        <p>
<bold>Renal Transplantation</bold>
</p>
        <p>As renal disease progresses toward ESRD, renal transplantation should be offered to patients. Although recipient monocytes may infiltrate donor kidneys with cystine crystals, renal tubular disease does not recur in the transplanted kidney. Renal transplantation generally has favorable long-term outcomes in cystinosis.<xref ref-type="bibr" rid="article-157501.r27">[27]</xref>&#x000a0;Long-term outcomes in cystinosis are generally considered superior to transplants for other etiologies.<xref ref-type="bibr" rid="article-157501.r5">[5]</xref>&#x000a0;Cysteamine must be continued after the&#x000a0;transplant to manage nonrenal complications.<xref ref-type="bibr" rid="article-157501.r28">[28]</xref></p>
        <p>
<bold>Future Therapies</bold>
</p>
        <p>Hematopoietic stem cell transplantation shows promise for treating cystinosis,<xref ref-type="bibr" rid="article-157501.r29">[29]</xref>&#x000a0;although current experience with this therapy is still preliminary.<xref ref-type="bibr" rid="article-157501.r30">[30]</xref><xref ref-type="bibr" rid="article-157501.r31">[31]</xref></p>
        <p>Inflammation plays a significant role in cystinosis pathology, with macrophages contributing to the inflammatory cycle. Galectin-3, an inflammatory mediator that attracts macrophages, has been used in animal models, and decreased expression of this molecule in humans is believed to be part of the therapeutic effect of indomethacin.<xref ref-type="bibr" rid="article-157501.r32">[32]</xref>&#x000a0;Other disease-modulating therapies, including mitochondrial oxygen scavengers such as Mito-TEMPO, have also been studied. Other proposed agents under evaluation include anakinra, an interleukin-1 antagonist, and leptin receptor blockers. However, none of these have been approved for clinical use.<xref ref-type="bibr" rid="article-157501.r10">[10]</xref><xref ref-type="bibr" rid="article-157501.r32">[32]</xref></p>
      </sec>
      <sec id="article-157501.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Other causes of Fanconi syndrome include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Tyrosinemia</p>
          </list-item>
          <list-item>
            <p>Galactosemia</p>
          </list-item>
          <list-item>
            <p>Glycogen storage disorders</p>
          </list-item>
          <list-item>
            <p>Wilson disease</p>
          </list-item>
          <list-item>
            <p>Lowe syndrome</p>
          </list-item>
          <list-item>
            <p>Hereditary fructose intolerance</p>
          </list-item>
          <list-item>
            <p>Mitochondrial disorders</p>
          </list-item>
          <list-item>
            <p>Monoclonal gammopathy</p>
          </list-item>
          <list-item>
            <p>Dent disease</p>
          </list-item>
        </list>
        <p>Heavy metal toxicities causing Fanconi syndrome include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Lead (in children)</p>
          </list-item>
          <list-item>
            <p>Cadmium</p>
          </list-item>
          <list-item>
            <p>Mercury</p>
          </list-item>
          <list-item>
            <p>Platinum</p>
          </list-item>
          <list-item>
            <p>Uranium&#x000a0;</p>
          </list-item>
        </list>
        <p>Conditions causing growth retardation with renal symptoms or episodes of dehydration include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Renal tubular acidosis (proximal and distal)</p>
          </list-item>
          <list-item>
            <p>Bartter syndrome</p>
          </list-item>
          <list-item>
            <p>Gitelman syndrome</p>
          </list-item>
          <list-item>
            <p>Diuretic abuse</p>
          </list-item>
        </list>
        <p>Genetic causes of vitamin D-resistant rickets include vitamin D&#x02013;dependent rickets types 1A, 1B, 2A, and 2B.</p>
      </sec>
      <sec id="article-157501.s10" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Previously, most patients with cystinosis died young due to complications, but early treatment with cysteamine now allows patients to survive to adulthood. Despite this, cystinosis continues to cause significant morbidity and increased mortality. While cysteamine therapy delays complications and reduces morbidity, no current treatment can offer a normal or near-normal life. Renal complications contribute to increased morbidity and often necessitate renal transplantation. In transplanted kidneys, cystine deposition does not recur. Gene therapy using hematopoietic stem cell transplantation shows future potential, but clinical experience remains limited.<xref ref-type="bibr" rid="article-157501.r31">[31]</xref></p>
      </sec>
      <sec id="article-157501.s11" sec-type="Complications">
        <title>Complications</title>
        <p>Cystinosis affects almost every organ system of the affected individual, with kidneys being the most commonly affected organ. Early signs include proximal renal tubular acidosis, characterized by multiple substance leaks, leading to Fanconi syndrome. Over time, GFR progressively declines, proteinuria often increases, and ESRD may develop, requiring renal replacement therapy.</p>
        <list list-type="bullet">
          <list-item>
            <p>Renal complications: Fanconi syndrome, dehydration episodes, hypokalemia, acidosis, hypophosphatemic rickets, and ESRD.</p>
          </list-item>
          <list-item>
            <p>Ocular complications: Corneal cystine deposition causing watering, photophobia, blepharospasm, and hemorrhagic retinopathy.</p>
          </list-item>
          <list-item>
            <p>Endocrine complications: Growth retardation, hypothyroidism, diabetes mellitus, and hypogonadism.</p>
          </list-item>
          <list-item>
            <p>Neurological and neuromuscular complications: Progressive loss of speech, memory, and intellectual function; cerebral calcification; and progressive myopathy causing swallowing and walking difficulties.</p>
          </list-item>
          <list-item>
            <p>Skeletal complications: Rickets, osteoporosis, renal osteodystrophy, and fragility fractures.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-157501.s12" sec-type="Consultations">
        <title>Consultations</title>
        <p>Pediatric nephrology, medical genetics, ophthalmology, pediatric endocrinology, neurology, urology, and physiotherapy are among the consultations to consider.</p>
      </sec>
      <sec id="article-157501.s13" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Cystinosis is an autosomal recessive genetic disorder with a known locus and predictable clinical course, with a 25% recurrence risk in offspring. Raising awareness through genetic counseling is crucial for prevention within affected families and the broader community. In addition to prevention, early recognition and prompt cysteamine treatment significantly reduce morbidity and delay mortality. Effective management of comorbidities and timely renal transplant referrals, along with cysteamine therapy, have a profoundly positive impact on the lives of affected families.</p>
      </sec>
      <sec id="article-157501.s14" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Similar to many hereditary multisystem conditions, managing cystinosis and taking&#x000a0;care of patients with this disorder require interprofessional team approach. Cystinosis is an inherited condition that often occurs in families with consanguineous unions. Patients or their families might seek help from general pediatricians and pediatric nephrologists or endocrinologists for symptoms such as polyuria, failure to thrive, or bony deformities. Ophthalmologists may be consulted for visual symptoms. Geneticists contribute to diagnosis through molecular genetic testing for <italic toggle="yes">CTNS</italic> variants and provide genetic counseling to affected families. Pediatric nephrology, pediatric endocrinology, ophthalmology, and neurology teams collaborate to manage the various manifestations of the condition. Physiotherapy and dietitian teams collaborate with specialists to address neuromuscular complications and manage special nutritional needs. The urology team assists in evaluating renal transplant requirements for patients with advanced renal failure.</p>
        <p>Care coordination is crucial for delivering seamless and efficient patient care. Physicians, advanced practitioners, nurses, pharmacists, and other healthcare professionals must collaborate closely from diagnosis through treatment and follow-up. This collaboration and teamwork minimizes errors, reduces delays, and enhances patient safety, ultimately leading to improved outcomes and patient-centered care that prioritizes the well-being and satisfaction of those affected by cystinosis.</p>
      </sec>
      <sec id="article-157501.s15">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=157501&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=157501">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/genetic-disorders/cystinosis/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=157501">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/157501/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=157501">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-157501.s16">
        <title>References</title>
        <ref id="article-157501.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gahl</surname>
                <given-names>WA</given-names>
              </name>
              <name>
                <surname>Thoene</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Schneider</surname>
                <given-names>JA</given-names>
              </name>
            </person-group>
            <article-title>Cystinosis.</article-title>
            <source>N Engl J Med</source>
            <year>2002</year>
            <month>Jul</month>
            <day>11</day>
            <volume>347</volume>
            <issue>2</issue>
            <fpage>111</fpage>
            <page-range>111-21</page-range>
            <pub-id pub-id-type="pmid">12110740</pub-id>
          </element-citation>
        </ref>
        <ref id="article-157501.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>David</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Princiero Berlingerio</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Elmonem</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Oliveira Arcolino</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Soliman</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>van den Heuvel</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Gijsbers</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Levtchenko</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Molecular Basis of Cystinosis: Geographic Distribution, Functional Consequences of Mutations in the CTNS Gene, and Potential for Repair.</article-title>
            <source>Nephron</source>
            <year>2019</year>
            <volume>141</volume>
            <issue>2</issue>
            <fpage>133</fpage>
            <page-range>133-146</page-range>
            <pub-id pub-id-type="pmid">30554218</pub-id>
          </element-citation>
        </ref>
        <ref id="article-157501.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Thoene</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lemons</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Anikster</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Mullet</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Paelicke</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Lucero</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Gahl</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Schneider</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Shu</surname>
                <given-names>SG</given-names>
              </name>
              <name>
                <surname>Campbell</surname>
                <given-names>HT</given-names>
              </name>
            </person-group>
            <article-title>Mutations of CTNS causing intermediate cystinosis.</article-title>
            <source>Mol Genet Metab</source>
            <year>1999</year>
            <month>Aug</month>
            <volume>67</volume>
            <issue>4</issue>
            <fpage>283</fpage>
            <page-range>283-93</page-range>
            <pub-id pub-id-type="pmid">10444339</pub-id>
          </element-citation>
        </ref>
        <ref id="article-157501.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>De Braekeleer</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gauthier</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Autosomal recessive disorders in Saguenay-Lac-Saint-Jean (Quebec, Canada): a study of inbreeding.</article-title>
            <source>Ann Hum Genet</source>
            <year>1996</year>
            <month>Jan</month>
            <volume>60</volume>
            <issue>1</issue>
            <fpage>51</fpage>
            <page-range>51-6</page-range>
            <pub-id pub-id-type="pmid">8835098</pub-id>
          </element-citation>
        </ref>
        <ref id="article-157501.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Elmonem</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Veys</surname>
                <given-names>KR</given-names>
              </name>
              <name>
                <surname>Soliman</surname>
                <given-names>NA</given-names>
              </name>
              <name>
                <surname>van Dyck</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>van den Heuvel</surname>
                <given-names>LP</given-names>
              </name>
              <name>
                <surname>Levtchenko</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Cystinosis: a review.</article-title>
            <source>Orphanet J Rare Dis</source>
            <year>2016</year>
            <month>Apr</month>
            <day>22</day>
            <volume>11</volume>
            <fpage>47</fpage>
            <pub-id pub-id-type="pmid">27102039</pub-id>
          </element-citation>
        </ref>
        <ref id="article-157501.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Thoene</surname>
                <given-names>JG</given-names>
              </name>
            </person-group>
            <article-title>A review of the role of enhanced apoptosis in the pathophysiology of cystinosis.</article-title>
            <source>Mol Genet Metab</source>
            <year>2007</year>
            <month>Dec</month>
            <volume>92</volume>
            <issue>4</issue>
            <fpage>292</fpage>
            <page-range>292-8</page-range>
            <pub-id pub-id-type="pmid">17728168</pub-id>
          </element-citation>
        </ref>
        <ref id="article-157501.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Levtchenko</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Endocrine Complications of Cystinosis.</article-title>
            <source>J Pediatr</source>
            <year>2017</year>
            <month>Apr</month>
            <volume>183S</volume>
            <fpage>S5</fpage>
            <page-range>S5-S8</page-range>
            <pub-id pub-id-type="pmid">28343475</pub-id>
          </element-citation>
        </ref>
        <ref id="article-157501.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Guillet</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Sassolas</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Fromentoux</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gobin</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Leroy</surname>
                <given-names>JP</given-names>
              </name>
            </person-group>
            <article-title>Skin storage of cystine and premature skin ageing in cystinosis.</article-title>
            <source>Lancet</source>
            <year>1998</year>
            <month>Oct</month>
            <day>31</day>
            <volume>352</volume>
            <issue>9138</issue>
            <fpage>1444</fpage>
            <page-range>1444-5</page-range>
            <pub-id pub-id-type="pmid">9807999</pub-id>
          </element-citation>
        </ref>
        <ref id="article-157501.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Servais</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Morini&#x000e8;re</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Gr&#x000fc;nfeld</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>No&#x000eb;l</surname>
                <given-names>LH</given-names>
              </name>
              <name>
                <surname>Goujon</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Chadefaux-Vekemans</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Antignac</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Late-onset nephropathic cystinosis: clinical presentation, outcome, and genotyping.</article-title>
            <source>Clin J Am Soc Nephrol</source>
            <year>2008</year>
            <month>Jan</month>
            <volume>3</volume>
            <issue>1</issue>
            <fpage>27</fpage>
            <page-range>27-35</page-range>
            <pub-id pub-id-type="pmid">18178779</pub-id>
          </element-citation>
        </ref>
        <ref id="article-157501.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sinopoli</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Khouri</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Failure to Thrive With Severe Hypokalemia Yields Cystinosis Diagnosis in a 19-Month-Old Female Child: A Case Report.</article-title>
            <source>Cureus</source>
            <year>2024</year>
            <month>Jun</month>
            <volume>16</volume>
            <issue>6</issue>
            <fpage>e63122</fpage>
            <pub-id pub-id-type="pmid">39055402</pub-id>
          </element-citation>
        </ref>
        <ref id="article-157501.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kanakaraj</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ravichandran</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Cystinosis Registry of India: Data Analysis of Patients with Cystinosis.</article-title>
            <source>Indian J Nephrol</source>
            <year>2024</year>
            <season>Jan-Feb</season>
            <volume>34</volume>
            <issue>1</issue>
            <fpage>100</fpage>
            <page-range>100-102</page-range>
            <pub-id pub-id-type="pmid">38645904</pub-id>
          </element-citation>
        </ref>
        <ref id="article-157501.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Anikster</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Lucero</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Guo</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Huizing</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Shotelersuk</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Bernardini</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>McDowell</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Iwata</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Kaiser-Kupfer</surname>
                <given-names>MI</given-names>
              </name>
              <name>
                <surname>Jaffe</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Thoene</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Schneider</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Gahl</surname>
                <given-names>WA</given-names>
              </name>
            </person-group>
            <article-title>Ocular nonnephropathic cystinosis: clinical, biochemical, and molecular correlations.</article-title>
            <source>Pediatr Res</source>
            <year>2000</year>
            <month>Jan</month>
            <volume>47</volume>
            <issue>1</issue>
            <fpage>17</fpage>
            <page-range>17-23</page-range>
            <pub-id pub-id-type="pmid">10625078</pub-id>
          </element-citation>
        </ref>
        <ref id="article-157501.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tsilou</surname>
                <given-names>ET</given-names>
              </name>
              <name>
                <surname>Rubin</surname>
                <given-names>BI</given-names>
              </name>
              <name>
                <surname>Reed</surname>
                <given-names>GF</given-names>
              </name>
              <name>
                <surname>Iwata</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Gahl</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Kaiser-Kupfer</surname>
                <given-names>MI</given-names>
              </name>
            </person-group>
            <article-title>Age-related prevalence of anterior segment complications in patients with infantile nephropathic cystinosis.</article-title>
            <source>Cornea</source>
            <year>2002</year>
            <month>Mar</month>
            <volume>21</volume>
            <issue>2</issue>
            <fpage>173</fpage>
            <page-range>173-6</page-range>
            <pub-id pub-id-type="pmid">11862089</pub-id>
          </element-citation>
        </ref>
        <ref id="article-157501.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tsilou</surname>
                <given-names>ET</given-names>
              </name>
              <name>
                <surname>Rubin</surname>
                <given-names>BI</given-names>
              </name>
              <name>
                <surname>Reed</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Caruso</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Iwata</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Balog</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gahl</surname>
                <given-names>WA</given-names>
              </name>
              <name>
                <surname>Kaiser-Kupfer</surname>
                <given-names>MI</given-names>
              </name>
            </person-group>
            <article-title>Nephropathic cystinosis: posterior segment manifestations and effects of cysteamine therapy.</article-title>
            <source>Ophthalmology</source>
            <year>2006</year>
            <month>Jun</month>
            <volume>113</volume>
            <issue>6</issue>
            <fpage>1002</fpage>
            <page-range>1002-9</page-range>
            <pub-id pub-id-type="pmid">16603246</pub-id>
          </element-citation>
        </ref>
        <ref id="article-157501.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gahl</surname>
                <given-names>WA</given-names>
              </name>
              <name>
                <surname>Kuehl</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Iwata</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Lindblad</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kaiser-Kupfer</surname>
                <given-names>MI</given-names>
              </name>
            </person-group>
            <article-title>Corneal crystals in nephropathic cystinosis: natural history and treatment with cysteamine eyedrops.</article-title>
            <source>Mol Genet Metab</source>
            <year>2000</year>
            <season>Sep-Oct</season>
            <volume>71</volume>
            <issue>1-2</issue>
            <fpage>100</fpage>
            <page-range>100-20</page-range>
            <pub-id pub-id-type="pmid">11001803</pub-id>
          </element-citation>
        </ref>
        <ref id="article-157501.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chiaverini</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Sillard</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Flori</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Ito</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Briganti</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Wakamatsu</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Fontas</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Berard</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Cailliez</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Cochat</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Foulard</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Guest</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Niaudet</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Picardo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bernard</surname>
                <given-names>FX</given-names>
              </name>
              <name>
                <surname>Antignac</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Ortonne</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Ballotti</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Cystinosin is a melanosomal protein that regulates melanin synthesis.</article-title>
            <source>FASEB J</source>
            <year>2012</year>
            <month>Sep</month>
            <volume>26</volume>
            <issue>9</issue>
            <fpage>3779</fpage>
            <page-range>3779-89</page-range>
            <pub-id pub-id-type="pmid">22649030</pub-id>
          </element-citation>
        </ref>
        <ref id="article-157501.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Emma</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Nesterova</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Langman</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Labb&#x000e9;</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Cherqui</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Goodyer</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Janssen</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Greco</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Topaloglu</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Elenberg</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Dohil</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Trauner</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Antignac</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Cochat</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Kaskel</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Servais</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>W&#x000fc;hl</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Niaudet</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Van't Hoff</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Gahl</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Levtchenko</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Nephropathic cystinosis: an international consensus document.</article-title>
            <source>Nephrol Dial Transplant</source>
            <year>2014</year>
            <month>Sep</month>
            <volume>29 Suppl 4</volume>
            <issue>Suppl 4</issue>
            <fpage>iv87</fpage>
            <page-range>iv87-94</page-range>
            <pub-id pub-id-type="pmid">25165189</pub-id>
          </element-citation>
        </ref>
        <ref id="article-157501.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brodin-Sartorius</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>T&#x000ea;te</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Niaudet</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Antignac</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Guest</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Ottolenghi</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Charbit</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Moyse</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Legendre</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Lesavre</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Cochat</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Servais</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Cysteamine therapy delays the progression of nephropathic cystinosis in late adolescents and adults.</article-title>
            <source>Kidney Int</source>
            <year>2012</year>
            <month>Jan</month>
            <volume>81</volume>
            <issue>2</issue>
            <fpage>179</fpage>
            <page-range>179-89</page-range>
            <pub-id pub-id-type="pmid">21900880</pub-id>
          </element-citation>
        </ref>
        <ref id="article-157501.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hohenfellner</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Nie&#x000df;l</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Haffner</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Oh</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Okorn</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Palm</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Schlingmann</surname>
                <given-names>KP</given-names>
              </name>
              <name>
                <surname>Wygoda</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gahl</surname>
                <given-names>WA</given-names>
              </name>
            </person-group>
            <article-title>Beneficial effects of starting oral cysteamine treatment in the first 2 months of life on glomerular and tubular kidney function in infantile nephropathic cystinosis.</article-title>
            <source>Mol Genet Metab</source>
            <year>2022</year>
            <month>Aug</month>
            <volume>136</volume>
            <issue>4</issue>
            <fpage>282</fpage>
            <page-range>282-288</page-range>
            <pub-id pub-id-type="pmid">35843134</pub-id>
          </element-citation>
        </ref>
        <ref id="article-157501.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Langman</surname>
                <given-names>CB</given-names>
              </name>
              <name>
                <surname>Greenbaum</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Grimm</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Sarwal</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Niaudet</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Deschenes</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Cornelissen</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Morin</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Cochat</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Elenberg</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Hanna</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Gaillard</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bagger</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Rioux</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Quality of life is improved and kidney function preserved in patients with nephropathic cystinosis treated for 2 years with delayed-release cysteamine bitartrate.</article-title>
            <source>J Pediatr</source>
            <year>2014</year>
            <month>Sep</month>
            <volume>165</volume>
            <issue>3</issue>
            <fpage>528</fpage>
            <page-range>528-33.e1</page-range>
            <pub-id pub-id-type="pmid">24948347</pub-id>
          </element-citation>
        </ref>
        <ref id="article-157501.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fiore</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Sohini</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Mileti</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Fiore</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Fibrosing Colonopathy Presenting in a Patient with Cystinosis.</article-title>
            <source>JPGN Rep</source>
            <year>2023</year>
            <month>Aug</month>
            <volume>4</volume>
            <issue>3</issue>
            <fpage>e321</fpage>
            <pub-id pub-id-type="pmid">37600607</pub-id>
          </element-citation>
        </ref>
        <ref id="article-157501.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Al-Hemidan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Shoughy</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Kozak</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Tabbara</surname>
                <given-names>KF</given-names>
              </name>
            </person-group>
            <article-title>Efficacy of topical cysteamine in nephropathic cystinosis.</article-title>
            <source>Br J Ophthalmol</source>
            <year>2017</year>
            <month>Sep</month>
            <volume>101</volume>
            <issue>9</issue>
            <fpage>1234</fpage>
            <page-range>1234-1237</page-range>
            <pub-id pub-id-type="pmid">28057644</pub-id>
          </element-citation>
        </ref>
        <ref id="article-157501.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Labb&#x000e9;</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Baudouin</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Desch&#x000ea;nes</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Loirat</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Charbit</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Guest</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Niaudet</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>A new gel formulation of topical cysteamine for the treatment of corneal cystine crystals in cystinosis: the Cystadrops OCT-1 study.</article-title>
            <source>Mol Genet Metab</source>
            <year>2014</year>
            <month>Mar</month>
            <volume>111</volume>
            <issue>3</issue>
            <fpage>314</fpage>
            <page-range>314-320</page-range>
            <pub-id pub-id-type="pmid">24440466</pub-id>
          </element-citation>
        </ref>
        <ref id="article-157501.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Levtchenko</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Servais</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hulton</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Ariceta</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Emma</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Game</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Lange</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Lapatto</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Liang</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Sberro-Soussan</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Topaloglu</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Das</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Webb</surname>
                <given-names>NJA</given-names>
              </name>
              <name>
                <surname>Wanner</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Expert guidance on the multidisciplinary management of cystinosis in adolescent and adult patients.</article-title>
            <source>Clin Kidney J</source>
            <year>2022</year>
            <month>Sep</month>
            <volume>15</volume>
            <issue>9</issue>
            <fpage>1675</fpage>
            <page-range>1675-1684</page-range>
            <pub-id pub-id-type="pmid">36003666</pub-id>
          </element-citation>
        </ref>
        <ref id="article-157501.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hohenfellner</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Rauch</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Ariceta</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Awan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bacchetta</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Bergmann</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bechtold</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Cassidy</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Deschenes</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Elenberg</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Gahl</surname>
                <given-names>WA</given-names>
              </name>
              <name>
                <surname>Greil</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Harms</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Herzig</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Hoppe</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Koeppl</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Lewis</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Levtchenko</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Nesterova</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Santos</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Schlingmann</surname>
                <given-names>KP</given-names>
              </name>
              <name>
                <surname>Servais</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Soliman</surname>
                <given-names>NA</given-names>
              </name>
              <name>
                <surname>Steidle</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Sweeney</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Treikauskas</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Topaloglu</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Tsygin</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Veys</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>V Vigier</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Zustin</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Haffner</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Management of bone disease in cystinosis: Statement from an international conference.</article-title>
            <source>J Inherit Metab Dis</source>
            <year>2019</year>
            <month>Sep</month>
            <volume>42</volume>
            <issue>5</issue>
            <fpage>1019</fpage>
            <page-range>1019-1029</page-range>
            <pub-id pub-id-type="pmid">31177550</pub-id>
          </element-citation>
        </ref>
        <ref id="article-157501.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Besouw</surname>
                <given-names>MTP</given-names>
              </name>
              <name>
                <surname>Van Dyck</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Francois</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Van Hoyweghen</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Levtchenko</surname>
                <given-names>EN</given-names>
              </name>
            </person-group>
            <article-title>Detailed studies of growth hormone secretion in cystinosis patients.</article-title>
            <source>Pediatr Nephrol</source>
            <year>2012</year>
            <month>Nov</month>
            <volume>27</volume>
            <issue>11</issue>
            <fpage>2123</fpage>
            <page-range>2123-2127</page-range>
            <pub-id pub-id-type="pmid">22664570</pub-id>
          </element-citation>
        </ref>
        <ref id="article-157501.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cohen</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Charbit</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Chadefaux-Vekemans</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Giral</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Garrigue</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Kessler</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Antoine</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Snanoudj</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Niaudet</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Kreis</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Legendre</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Servais</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Excellent long-term outcome of renal transplantation in cystinosis patients.</article-title>
            <source>Orphanet J Rare Dis</source>
            <year>2015</year>
            <month>Jul</month>
            <day>25</day>
            <volume>10</volume>
            <fpage>90</fpage>
            <pub-id pub-id-type="pmid">26208493</pub-id>
          </element-citation>
        </ref>
        <ref id="article-157501.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Berryhill</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bhamre</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Chaudhuri</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Concepcion</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Grimm</surname>
                <given-names>PC</given-names>
              </name>
            </person-group>
            <article-title>Cysteamine in renal transplantation: A report of two patients with nephropathic cystinosis and the successful re-initiation of cysteamine therapy during the immediate post-transplant period.</article-title>
            <source>Pediatr Transplant</source>
            <year>2016</year>
            <month>Feb</month>
            <volume>20</volume>
            <issue>1</issue>
            <fpage>141</fpage>
            <page-range>141-5</page-range>
            <pub-id pub-id-type="pmid">26477696</pub-id>
          </element-citation>
        </ref>
        <ref id="article-157501.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cherqui</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Hematopoietic Stem Cell Gene Therapy for Cystinosis: From Bench-to-Bedside.</article-title>
            <source>Cells</source>
            <year>2021</year>
            <month>Nov</month>
            <day>23</day>
            <volume>10</volume>
            <issue>12</issue>
            <pub-id pub-id-type="pmid">34943781</pub-id>
          </element-citation>
        </ref>
        <ref id="article-157501.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Elmonem</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Veys</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Oliveira Arcolino</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Van Dyck</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Benedetti</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Diomedi-Camassei</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>De Hertogh</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>van den Heuvel</surname>
                <given-names>LP</given-names>
              </name>
              <name>
                <surname>Renard</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Levtchenko</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Allogeneic HSCT transfers wild-type cystinosin to nonhematological epithelial cells in cystinosis: First human report.</article-title>
            <source>Am J Transplant</source>
            <year>2018</year>
            <month>Nov</month>
            <volume>18</volume>
            <issue>11</issue>
            <fpage>2823</fpage>
            <page-range>2823-2828</page-range>
            <pub-id pub-id-type="pmid">30030899</pub-id>
          </element-citation>
        </ref>
        <ref id="article-157501.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cherqui</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>[Cystinosis: From the gene identification to the first gene therapy clinical trial].</article-title>
            <source>Med Sci (Paris)</source>
            <year>2023</year>
            <month>Mar</month>
            <volume>39</volume>
            <issue>3</issue>
            <fpage>253</fpage>
            <page-range>253-261</page-range>
            <pub-id pub-id-type="pmid">36943122</pub-id>
          </element-citation>
        </ref>
        <ref id="article-157501.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Elmonem</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Veys</surname>
                <given-names>KRP</given-names>
              </name>
              <name>
                <surname>Prencipe</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Nephropathic Cystinosis: Pathogenic Roles of Inflammation and Potential for New Therapies.</article-title>
            <source>Cells</source>
            <year>2022</year>
            <month>Jan</month>
            <day>06</day>
            <volume>11</volume>
            <issue>2</issue>
            <pub-id pub-id-type="pmid">35053306</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
